NanoBio Corporation

Website Links

Description

Dr. Smith joined NanoBio in November 2013 with over 20 years of experience in immunology including cellular and antibody-based immunotherapies and vaccines against cancer and infectious diseases. He received a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Immunology from The University of Chicago.

Dr. Cresswell is the former Senior Vice President and Chief Scientific Officer of Warner-Lambert, and has served on the Board of Directors of Esperion Therapeutics, Inc., Allergan, Inc., Curagen Corporation, and Vasogen, Inc. He brings over 30 years of research and commercial development experience in various therapeutic areas to NanoBio. Dr. Cresswell began his tenure with Warner-Lambert in 1988 as the President of Research and Development of the Parke-Davis Pharmaceutical Research Division.

NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, based on its patented NanoStat™ technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates include vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax and HSV2. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease.

Dr. Bitko has over 20 years of experience in virology, biochemistry and molecular biology including development of non-adjuvanted and adjuvanted viral vaccines and anti-virals. She joined NanoBio in July 2011 after having served as a Principal Virologist at Meridian Life Science where she was involved in development of viral vaccines, recombinant protein biotherapeutic production, analytical test method development and validation. Dr.

Dr. Hamouda has over 16 years of experience in antimicrobial drug and vaccine development and over 12 years of experience at NanoBio where he directed pre-clinical research, contributed to phase 1, 2 and 3 drug development and led phase 1 clinical vaccine development. Dr. Hamouda received his MD and his PhD in microbiology and immunology from the Faculty of Medicine, Cairo University. He had his post-doctoral work at Wayne State University focused on the development of a treatment for HIV using Herpes simplex virus virion host shut-off gene. In 1997, he joined Dr.

Fact sheet

Company contacts

Products & services

Similar companies nearby